Advertisement
News
Advertisement

New Clinical Data Highlighting Foundation Medicine's Comprehensive Cancer Genomic Profile to be Presented at 2012 ASCO Annual Meeting

Wed, 05/16/2012 - 2:45pm
The Associated Press

CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 16, 2012-- Foundation Medicine, Inc., a molecular information company that brings comprehensive cancer genomic analysis to routine clinical care, today announced that new clinical data highlighting the company's comprehensive cancer genomic profile and next-generation sequencing approach in clinical oncology will be presented at the 2012 Annual Meeting of the American Society for Clinical Oncology (ASCO) being held June 1-5, 2012 in Chicago.

"The data to be presented at ASCO support Foundation Medicine's deep sequencing approach to simultaneously detect all classes of genomic alterations across hundreds of genes known to be related to cancer," said Michael J. Pellini, M.D., president and chief executive officer, Foundation Medicine. "In our clinical experience abstract, this approach detected actionable alterations- those associated with available targeted treatments or ongoing clinical trials- for 74% of tumor samples in the study. Foundation Medicine's test has also been shown to identify novel genomic alterations in multiple tumor types, including potentially druggable gene fusions. The combined evidence presented in these studies suggests that fully informative genomic profiling can now become a routine component of cancer patient care." The schedule for Foundation Medicine's oral presentation is as follows: Date & Time:   Saturday, June 2 from 8:00 to 9:30 a.m. (CT); presentation from 9:00 a.m. to 9:15 a.m. (CT) Session: Clinical Science Symposium Abstract Number: 7510 Title: Discovery of recurrent KIF5B-RET fusions and other targetable alterations from clinical NSCLC specimens.

Location: E Hall D2 Collaborator: Dana-Farber Cancer Institute The schedule for Foundation Medicine's poster discussion presentations is as follows: Date & Time:   Friday, June 1 from 1:00 to 5:00 p.m. (CT); discussion from 4:30 to 5:30 p.m. (CT) Abstract Number: 3533 Title: Use of next-generation sequencing (NGS) to detect a novel ALK fusion and a high frequency of other actionable alterations in colorectal cancer (CRC).

Poster Number: 25 Location: E450b; discussion in E Arie Crown Collaborator: Albany Medical College Date & Time:   Monday, June 4 from 1:15 to 5:15 p.m. (CT); discussion from 4:45 to 5:45 p.m. (CT) Abstract Number: 1015 Title: Cancer gene profile of metastatic breast cancer.

Poster Number: 7 Location: E450b; discussion in N Hall B1 Collaborator: M.D. Anderson Cancer Center Date & Time:   Tuesday, June 5 from 8:00 a.m. to 12:00 p.m. (CT); discussion from 11:30 a.m. to 12:30 p.m. (CT) Abstract Number: 7529 Title: Concordance of driver mutations in primary and matched metastasis from patients with non-small cell lung cancer (NSCLC) using next-generation sequencing (NGS).

Poster Number: 19 Location: E450a; discussion in E354a Collaborator: Institut Gustav Roussy Date & Time:   Tuesday, June 5 from 8:00 a.m. to 12:00 p.m. (CT); discussion from 11:30 a.m. to 12:30 p.m. (CT) Abstract Number: 10524 Title: Next-generation sequencing of FFPE solid tumor specimens for clinical use.

Poster Number: 17 Location: S102; discussion in S100a Collaborator: Memorial Sloan Kettering Cancer Center and University of California, San Francisco The schedule for Foundation Medicine's general poster session presentations is as follows: Date & Time:   Sunday, June 3 from 8:00 a.m. to 12:00 p.m. (CT) Abstract Number: 4649 Title: Targeted next-generation sequencing (NGS) of advanced prostate cancer (PCA) using formalin-fixed tissue.

Poster Number: 10H Location: S Hall A2 Collaborator: Weill Cornell Medical College Date & Time:   Monday, June 4 from 1:15 to 5:15 p.m. (CT) Abstract Number: 10559 Title: Next-generation sequencing (NGS) detects high-frequency of targetable alterations in primary and metastatic breast cancer (MBC).

Poster Number: 44H Location: S Hall A2 Collaborator: M.D. Anderson Cancer Center Date & Time:   Monday, June 4 from 1:15 to 5:15 p.m. (CT) Abstract Number: 10590 Title: Next-generation sequencing (NGS) to identify actionable genomic changes in common and rare solid tumors: The FMI experience with the initial 50 consecutive patients.

Poster Number: 48G Location: S Hall A2 About Foundation Medicine's Comprehensive Cancer Genomic Profile Foundation Medicine's first clinical product is a fully informative genomic profile that complements traditional cancer treatment decision tools and often expands options by matching each patient with targeted therapies that are relevant to the molecular changes in their tumor.

The profile is the first commercially available targeted sequencing assay utilizing clinical grade next-generation sequencing (NGS) in routine cancer specimens. Foundation Medicine's assay identifies all classes of genomic alterations (including copy number alterations, insertions, deletions and rearrangements) in approximately 200 cancer-related genes. Genomic profile results are reported to the physician along with targeted therapies and clinical trials that may be relevant to each individual patient based on the most recent scientific and medical research. Foundation Medicine operates a CLIA-certified lab and will formally launch its commercial clinical laboratory services in mid-2012.

About Foundation Medicine Foundation Medicine is a molecular information company dedicated to a transformation in cancer care in which treatment is informed by a deep understanding of the genomic changes that contribute to each patient's unique cancer. The company has developed a fully informative genomic profile to identify a patient's individual molecular alterations and match them with relevant targeted therapies and clinical trials.

Foundation Medicine's molecular information platform aims to improve day-to-day care for patients by serving the needs of clinicians, academic researchers and drug developers to help advance the science of molecular medicine in cancer. For more information, please visit the company's website www.foundationmedicine.com.

CONTACT: Pure Communications, Inc.

Dan Budwick, 973-271-6085 KEYWORD: UNITED STATES NORTH AMERICA MASSACHUSETTS INDUSTRY KEYWORD: HEALTH GENETICS ONCOLOGY SOURCE: Foundation Medicine, Inc.

Copyright Business Wire 2012 PUB: 05/16/2012 06:00 PM/DISC: 05/16/2012 06:00 PM http://www.businesswire.com/news/home/20120516006947/

Advertisement

Share this Story

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading